• The paper was based on a presentation given at a satellite symposium held at the European Association of Urology (EAU) 2008 annual congress in Milan, Italy. Data were retrieved from recent review articles, original articles, and abstracts on neoadjuvant or adjuvant HT in PCa.
• Luteinising hormone-releasing hormone agonists have become HT of choice. Neoadjuvant ADT to RP seems to induce pathological downstaging (1) but does not offer survival benefit over RP alone in localised PCa (2). Short-term neoadjuvant ADT to RT may result in increased survival compared with RT alone in locally advanced PCa but appears specifically indicated in patients with Gleason score 2-6 (3,4).
Copyright © 